[go: up one dir, main page]

WO2014006025A3 - Marker of pathogenicity in salmonella - Google Patents

Marker of pathogenicity in salmonella Download PDF

Info

Publication number
WO2014006025A3
WO2014006025A3 PCT/EP2013/063900 EP2013063900W WO2014006025A3 WO 2014006025 A3 WO2014006025 A3 WO 2014006025A3 EP 2013063900 W EP2013063900 W EP 2013063900W WO 2014006025 A3 WO2014006025 A3 WO 2014006025A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathogenicity
salmonella
marker
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/063900
Other languages
French (fr)
Other versions
WO2014006025A2 (en
Inventor
Miguel Angel DE LA CRUZ VILLEGAS
Stéphane MERESSE
Jean-Pierre Gorvel
Didier Raoult
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Aix Marseille Universite
Publication of WO2014006025A2 publication Critical patent/WO2014006025A2/en
Publication of WO2014006025A3 publication Critical patent/WO2014006025A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to marker(s) of pathogenicity in Salmonella and the uses thereof.
PCT/EP2013/063900 2012-07-02 2013-07-02 Marker of pathogenicity in salmonella Ceased WO2014006025A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305791 2012-07-02
EP12305791.1 2012-07-02

Publications (2)

Publication Number Publication Date
WO2014006025A2 WO2014006025A2 (en) 2014-01-09
WO2014006025A3 true WO2014006025A3 (en) 2014-04-17

Family

ID=48790378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/063900 Ceased WO2014006025A2 (en) 2012-07-02 2013-07-02 Marker of pathogenicity in salmonella

Country Status (1)

Country Link
WO (1) WO2014006025A2 (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US852444A (en) 1906-12-05 1907-05-07 Carl J Mellin Locomotive.
US4358535A (en) 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
FI63596C (en) 1981-10-16 1983-07-11 Orion Yhtymae Oy MICROBIA DIAGNOSIS FOERFARANDE SOM GRUNDAR SIG PAO SKIKTSHYBRIDISERING AV NUCLEINSYROR OCH VID FOERFARANDET ANVAENDA KOMBINATIONER AV REAGENSER
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 22 February 2012 (2012-02-22), "SubName: Full=Sea40;", XP002687496, retrieved from EBI accession no. UNIPROT:H0M6R6 Database accession no. H0M6R6 *
MAKAROVA KIRA S ET AL: "Comprehensive comparative-genomic analysis of Type 2 toxin-antitoxin systems and related mobile stress response systems in prokaryotes", BIOLOGY DIRECT, BIOMED CENTRAL LTD, LO, vol. 4, no. 1, 3 June 2009 (2009-06-03), pages 19 - 57, XP021059831, ISSN: 1745-6150 *
MARC W ALLARD ET AL: "High resolution clustering of Salmonella enterica serovar Montevideo strains using a next-generation sequencing approach", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 13, no. 1, 19 January 2012 (2012-01-19), pages 32 - 51, XP021094871, ISSN: 1471-2164, DOI: 10.1186/1471-2164-13-32 *
SHAO ET AL.: "Type 2 toxin-antitoxin - Salmonella enterica subsp. enterica serovar Typhi str. Ty2 (pairs)", 3 June 2009 (2009-06-03), XP002694006, Retrieved from the Internet <URL:http://bioinfo-mml.sjtu.edu.cn/TADB/browse_result.php?type=id&org_id=60> [retrieved on 20130315] *
SHAO ET AL.: "Type 2 toxin-antitoxin - t3590 Salmonella enterica subsp. enterica serovar Typhi str. Ty2 (toxin)", 3 June 2009 (2009-06-03), XP002694005, Retrieved from the Internet <URL:http://bioinfo-mml.sjtu.edu.cn/TADB/feature_page.php?feature_id=1664017> [retrieved on 20130315] *
SHAO ET AL.: "Type 2 toxin-antitoxin - t3591 Salmonella enterica subsp. enterica serovar Typhi str. Ty2 (antitoxin)", 3 June 2009 (2009-06-03), XP002687501, Retrieved from the Internet <URL:http://bioinfo-mml.sjtu.edu.cn/TADB/feature_page.php?feature_id=1664020> [retrieved on 20121003] *
Y. SHAO ET AL: "TADB: a web-based resource for Type 2 toxin-antitoxin loci in bacteria and archaea", NUCLEIC ACIDS RESEARCH, vol. 39, no. Suppl. 1, 1 January 2011 (2011-01-01), pages D606 - D611, XP055039846, ISSN: 0305-1048, DOI: 10.1093/nar/gkq908 *

Also Published As

Publication number Publication date
WO2014006025A2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
IL238192A0 (en) Antibodies recognizing alpha-synnuclein, compositions comprising same and uses thereof
IL237625A0 (en) Anti-mcam antibodies, compositions comprising same and uses thereof
IL236348A0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
JO3343B1 (en) Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use
IL234014A (en) Cycloalkane derivatives, compositions comprising same and uses thereof
EP3060561A4 (en) Strigolactone formulations and uses thereof
IL235004A0 (en) Anti-fgfr2 antibodies, compositions comprising same and uses thereof
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
WO2013163297A8 (en) Modified glycoproteins
WO2013190274A3 (en) Biodegradable compositions
EP2874641A4 (en) Glutathione-elevating compositions and uses thereof
WO2013155338A8 (en) Substituted benzamides and their uses
IL236568A0 (en) Alkylthiophene-rich compositions, uses thereof and methods of manufacturing the same
HUE037525T2 (en) Snorna, compositions and uses
IL233682A0 (en) Substituted phenylazole derivatives, compositions comprising same and uses thereof
EP2902480A4 (en) Paecilomyces variotii var. brunneolus gpp1101b, and preparation using same
GB201208384D0 (en) Vesicular formulations, uses and methods
GB201208409D0 (en) Vesicular formulations, kits and uses
EP3057972A4 (en) Novel compositions, uses and methods for their preparation
EP2945703A4 (en) Formulations of albu-bche, preparation and uses thereof
MX345908B (en) Edible energy composition.
SG11201502069SA (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
WO2013181572A3 (en) Methods related to panitumumab

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13736822

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13736822

Country of ref document: EP

Kind code of ref document: A2